199 related articles for article (PubMed ID: 33686916)
1. Emapalumab for adult and pediatric patients with hemophagocytic lymphohistiocytosis.
Garonzi C; Chinello M; Cesaro S
Expert Rev Clin Pharmacol; 2021 May; 14(5):527-534. PubMed ID: 33686916
[TBL] [Abstract][Full Text] [Related]
2. Emapalumab for the treatment of hemophagocytic lymphohistiocytosis.
Cheloff AZ; Al-Samkari H
Drugs Today (Barc); 2020 Jul; 56(7):439-446. PubMed ID: 32648854
[TBL] [Abstract][Full Text] [Related]
3. Emapalumab: First Global Approval.
Al-Salama ZT
Drugs; 2019 Jan; 79(1):99-103. PubMed ID: 30623346
[TBL] [Abstract][Full Text] [Related]
4. Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis.
Locatelli F; Jordan MB; Allen C; Cesaro S; Rizzari C; Rao A; Degar B; Garrington TP; Sevilla J; Putti MC; Fagioli F; Ahlmann M; Dapena Diaz JL; Henry M; De Benedetti F; Grom A; Lapeyre G; Jacqmin P; Ballabio M; de Min C
N Engl J Med; 2020 May; 382(19):1811-1822. PubMed ID: 32374962
[TBL] [Abstract][Full Text] [Related]
5. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis.
Vallurupalli M; Berliner N
Blood; 2019 Nov; 134(21):1783-1786. PubMed ID: 31537529
[TBL] [Abstract][Full Text] [Related]
6. Novel Therapeutic Approaches to Familial HLH (Emapalumab in FHL).
Merli P; Algeri M; Gaspari S; Locatelli F
Front Immunol; 2020; 11():608492. PubMed ID: 33424859
[TBL] [Abstract][Full Text] [Related]
7. Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab.
Chandrakasan S; Jordan MB; Baker A; Behrens EM; Bhatla D; Chien M; Eckstein OS; Henry MM; Hermiston ML; Hinson AP; Leiding JW; Oladapo A; Patel SA; Pednekar P; Ray AK; Dávila Saldaña B; Sarangi SN; Walkovich KJ; Yee JD; Zoref-Lorenz A; Allen CE
Blood Adv; 2024 May; 8(9):2248-2258. PubMed ID: 38429096
[TBL] [Abstract][Full Text] [Related]
8. Emapalumab treatment in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis-related graft failure and disseminated bacillus Calmette-Guérin infection.
Tucci F; Gallo V; Barzaghi F; Ferrua F; Migliavacca M; Calbi V; Doglio M; Fratini ES; Karakas Z; Guner S; Zambelli M; Parisi C; Milani R; Gattillo S; Mazzi B; Oltolini C; Barbera M; Baldoli C; Cirillo DM; Asnaghi V; De Min C; Cicalese MP; Ciceri F; Aiuti A; Bernardo ME
Haematologica; 2021 Feb; 106(2):641-646. PubMed ID: 32817285
[TBL] [Abstract][Full Text] [Related]
9. Successful use of emapalumab in refractory hemophagocytic lymphohistiocytosis in a child with Chédiak-Higashi syndrome: a case report.
AlAhmari A; Khogeer H
J Med Case Rep; 2023 Mar; 17(1):113. PubMed ID: 36978158
[TBL] [Abstract][Full Text] [Related]
10. Exposure-safety relationship for patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab.
Jordan MB; Locatelli F
Pediatr Blood Cancer; 2024 Feb; 71(2):e30778. PubMed ID: 38014905
[TBL] [Abstract][Full Text] [Related]
11. Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: A pharmacometric model-based approach.
Jacqmin P; Laveille C; Snoeck E; Jordan MB; Locatelli F; Ballabio M; de Min C
Br J Clin Pharmacol; 2022 May; 88(5):2128-2139. PubMed ID: 34935183
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of the Anti-Interferon-Gamma Monoclonal Antibody Emapalumab: An Updated Analysis.
Brossard P; Laveille C
Rheumatol Ther; 2024 Jun; 11(3):869-880. PubMed ID: 38662147
[TBL] [Abstract][Full Text] [Related]
13. Combined Use of Emapalumab With Ruxolitinib and Dexamethasone as an Effective Treatment for Epstein-Barr Virus-associated Hemophagocytic Lymphohistiocytosis Complicated With Multiorgan Damage and Severe Infection.
Liang J; Xu X; Chen Z; Yu J; Tang Y
J Pediatr Hematol Oncol; 2024 Jul; 46(5):e360-e362. PubMed ID: 38691058
[TBL] [Abstract][Full Text] [Related]
14. A Review of Current and Emerging Therapeutic Options for Hemophagocytic Lymphohistiocytosis.
Summerlin J; Wells DA; Anderson MK; Halford Z
Ann Pharmacother; 2023 Jul; 57(7):867-879. PubMed ID: 36349896
[TBL] [Abstract][Full Text] [Related]
15. Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy.
Gloude NJ; Dandoy CE; Davies SM; Myers KC; Jordan MB; Marsh RA; Kumar A; Bleesing J; Teusink-Cross A; Jodele S
J Clin Immunol; 2020 Jul; 40(5):699-707. PubMed ID: 32447592
[TBL] [Abstract][Full Text] [Related]
16. Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections.
Lounder DT; Bin Q; de Min C; Jordan MB
Blood Adv; 2019 Jan; 3(1):47-50. PubMed ID: 30617216
[TBL] [Abstract][Full Text] [Related]
17. Case report: Emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.
Chellapandian D; Milojevic D
Front Pediatr; 2023; 11():1123104. PubMed ID: 36891226
[TBL] [Abstract][Full Text] [Related]
18. Systemic and Nodular Hyperinflammation in a Patient with Refractory Familial Hemophagocytic Lymphohistiocytosis 2.
Segal JE; Daley JD; Barnum JL; Salgado CM; Reyes-Mugica M; Schneider C; Gumus S; Thakrar D; Allen SW; Canna SW
J Clin Immunol; 2021 Jul; 41(5):987-991. PubMed ID: 33570715
[TBL] [Abstract][Full Text] [Related]
19. Hemophagocytic lymphohistocytosis in trisomy 21: successful treatment with interferon inhibition.
Guild A; Fritch J; Patel S; Reinhardt A; Acquazzino M
Pediatr Rheumatol Online J; 2022 Nov; 20(1):104. PubMed ID: 36401314
[TBL] [Abstract][Full Text] [Related]
20. Treatment of pediatric primary hemophagocytic lymphohistiocytosis with the HLH-94/2004 regimens and hematopoietic stem cell transplantation in China.
Ma H; Zhang R; Zhang L; Wei A; Zhao X; Yang Y; Liu W; Li Z; Qin M; Wang T
Ann Hematol; 2020 Oct; 99(10):2255-2263. PubMed ID: 32766934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
